Category: biotech

.Along with a solid record for recognizing diamonds in the rough, Bain Financing Daily Life Sciences (BCLS) has actually ended up being a strong interject

.Welcome to today’s Chutes &amp Ladders, our roundup of considerable leadership hirings, firings and retirings throughout the business. Satisfy deliver the compliment– or the negative–

.Bristol Myers Squibb is actually spending Prime Medication $110 million ahead of time to create reagents for ex vivo T-cell therapies. Prime, which might get

.Bristol Myers Squibb is actually axing one more huge wager from the Caforio era, ending a bargain for Agenus’ TIGIT bispecific antitoxin 3 years after

.Bristol Myers Squibb has possessed a whiplash change of mind on its BCMA bispecific T-cell engager, halting (PDF) additional advancement months after filing to run

.AvenCell Therapeutics has actually secured $112 million in series B funds as the Novo Holdings-backed biotech looks for medical verification that it can produce CAR-T

.Atea Pharmaceuticals’ antiviral has failed another COVID-19 test, but the biotech still stores out really hope the applicant has a future in hepatitis C.The dental

.AstraZeneca has discussed a very early check out the efficiency of its own internal antibody-drug conjugate (ADC) modern technology, posting phase 1 information on candidates

.Pinetree Rehabs are going to assist AstraZeneca vegetation some plants in its own pipeline with a new deal to cultivate a preclinical EGFR degrader worth

.AstraZeneca has actually paid CSPC Drug Group $one hundred thousand for a preclinical cardiovascular disease drug. The offer, which covers a possible opponent to an